Syngene International Ltd
NSE:SYNGENE
Syngene International Ltd
In the bustling landscape of the global pharmaceutical industry, Syngene International Ltd. stands out as a beacon of scientific innovation and strategic acumen. Founded in 1993, this Bangalore-based contract research and manufacturing organization (CRMO) has carved a niche by seamlessly blending cutting-edge research with commercial savvy. Syngene offers integrated services spanning the entire drug discovery and development continuum, catering to diverse sectors including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. By providing end-to-end solutions, from target identification and discovery chemistry to pre-clinical and clinical development and up to commercial manufacturing, Syngene ensures that its clients can focus on their core competencies, thus accelerating their journey from lab to market.
Syngene's revenue model thrives on fostering long-term partnerships with global giants such as Bristol-Myers Squibb, Amgen, and Baxter, who rely on the company's deep scientific expertise and robust infrastructure. By offering bespoke solutions that address specific client needs, Syngene generates income through flexible, multi-year contracts and milestone payments at various stages of the drug development cycle. This approach not only ensures a steady revenue stream but also strengthens Syngene's reputation as a trusted partner in scientific innovation. With their state-of-the-art facilities and a team of world-class scientists, Syngene effectively marries scientific curiosity with business excellence, driving the future of health sciences and securing its position as a pivotal player in the CRMO field.
In the bustling landscape of the global pharmaceutical industry, Syngene International Ltd. stands out as a beacon of scientific innovation and strategic acumen. Founded in 1993, this Bangalore-based contract research and manufacturing organization (CRMO) has carved a niche by seamlessly blending cutting-edge research with commercial savvy. Syngene offers integrated services spanning the entire drug discovery and development continuum, catering to diverse sectors including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. By providing end-to-end solutions, from target identification and discovery chemistry to pre-clinical and clinical development and up to commercial manufacturing, Syngene ensures that its clients can focus on their core competencies, thus accelerating their journey from lab to market.
Syngene's revenue model thrives on fostering long-term partnerships with global giants such as Bristol-Myers Squibb, Amgen, and Baxter, who rely on the company's deep scientific expertise and robust infrastructure. By offering bespoke solutions that address specific client needs, Syngene generates income through flexible, multi-year contracts and milestone payments at various stages of the drug development cycle. This approach not only ensures a steady revenue stream but also strengthens Syngene's reputation as a trusted partner in scientific innovation. With their state-of-the-art facilities and a team of world-class scientists, Syngene effectively marries scientific curiosity with business excellence, driving the future of health sciences and securing its position as a pivotal player in the CRMO field.
Revenue Decline: Q3 revenue from operations fell 3% year-on-year to INR 917 crores due to ongoing headwinds from a single large molecule biologics customer.
FY26 Guidance Cut: Full-year guidance revised to a 3%–5% revenue decline and operating EBITDA margin of 22%–23%, citing the continued impact from the single product.
Underlying Growth: Excluding the affected product, the rest of the business is growing at high single to low double digits, with steady progress in both Research Services and CDMO.
Strategic Investments: Company continues to invest in new facilities, scientific capabilities, and technology upgrades, including a new US biologics site and expanded chemistry labs.
Bristol Myers Squibb Partnership: Long-term partnership with BMS extended to 2035, reinforcing strong client relationships.
Product Impact Duration: Management expects the negative impact from the single product to persist for several more quarters beyond Q4.
